Edap Tms Sa ADR (EDAP) 3.23 $EDAP
EDAP First Quarter 2016 Revenue Increases 40% Year-over-Year to EUR8.7 Million
GlobeNewswire - Wed May 18, 6:00AM CDT
-- First quarter 2016 HIFU Division revenue increased 102% year-over-year
EDAP: 3.23 (-0.02)
EDAP to Report First Quarter 2016 Results on May 18, 2016
GlobeNewswire - Tue May 10, 7:30AM CDT
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that it plans to release financial results for the first quarter ended March 31, 2016, on May 18, 2016, during pre-market hours.
EDAP: 3.23 (-0.02)
EDAP Announces Presentations and Live Demonstrations of Ablatherm(R) Robotic HIFU at 2016 American Urology Association Annual Meeting, May 6-10, 2016
GlobeNewswire - Wed May 04, 7:30AM CDT
Company to Participate in Two Plenary Sessions and Five Poster Sessions
EDAP: 3.23 (-0.02)
EDAP Receives Brazilian Regulatory Approval for Focal One(R) HIFU Device
GlobeNewswire - Thu Apr 28, 7:30AM CDT
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that The Brazilian Health Surveillance Agency (Anvisa) has approved Focal One for sale in Brazil.
EDAP: 3.23 (-0.02)
Houston Methodist Hospital, Houston, TX Acquires and Installs EDAP's Ablatherm(R) Robotic HIFU
GlobeNewswire - Mon Apr 25, 7:36AM CDT
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced the sale and installation of Ablatherm Robotic HIFU at Houston Methodist Hospital, Houston, Texas. The hospital is the first location in Texas to install EDAP's noninvasive HIFU device for the ablation of prostate tissue.
EDAP: 3.23 (-0.02)
EDAP's Ablatherm(R) Robotic HIFU Deployed by HIFU Solution
GlobeNewswire - Mon Apr 18, 7:30AM CDT
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced the first prostate ablation treatments performed in Orlando, Florida, using the Company's FDA-cleared Ablatherm Robotic HIFU.
EDAP: 3.23 (-0.02)
EDAP TMS SA Closes $11.5 Million Registered Direct Offering
GlobeNewswire - Thu Apr 14, 2:15PM CDT
Positions EDAP to Accelerate U.S. Sales and Marketing Expansion for HIFU
EDAP: 3.23 (-0.02)
EDAP TMS SA to Raise $11.5 Million in Registered Direct Offering
GlobeNewswire - Thu Apr 07, 8:13AM CDT
EDAP TMS SA (Nasdaq:EDAP), a global leader in therapeutic ultrasound, announced that it has entered into definitive agreements with certain institutional investors for a registered direct placement of 3,283,284 ordinary shares in the form of American Depositary Shares ("ADSs"
at a price of $3.50 per share.
EDAP: 3.23 (-0.02)
EDAP Submits 510(k) Application for FDA Clearance of Focal One HIFU
GlobeNewswire - Wed Apr 06, 6:55AM CDT
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that it has submitted a 510(k) application to the U.S. Food and Drug Administration (FDA) for the clearance of its next generation HIFU device: the Focal One. This submission follows the November 2015 FDA clearance of Ablatherm Robotic HIFU for the ablation of prostate tissue.
EDAP: 3.23 (-0.02)
EDAP Reports 20% Revenue Growth to EUR 32.3 Million and EUR 0.5 Million Operating Profit for Full-year 2015
GlobeNewswire - Mon Apr 04, 6:00AM CDT
-- Obtained FDA clearance in November 2015 for Ablatherm Robotic HIFU;
EDAP: 3.23 (-0.02)
EDAP to Report Fourth Quarter and Full Year 2015 Results on April 4, 2016
GlobeNewswire - Thu Mar 24, 7:30AM CDT
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that it plans to release financial results for the fourth quarter and full year ended December 31, 2015, on April 4, 2016, during pre-market hours.
EDAP: 3.23 (-0.02)
EDAP HIFU Advancements Highlighted at International Symposium on Therapeutic Ultrasound
GlobeNewswire - Tue Mar 22, 7:30AM CDT
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that its advancements in High Intensity Focused Ultrasound (HIFU) were highlighted at the International Symposium on Therapeutic Ultrasound (ISTU 2016), which took place from March 14-17, 2016, in Tel Aviv, Israel. At ISTU 2016, HIFU experts from EDAP and the Company's long-time academic partner, INSERM, presented their most recent advances in the development of therapeutic focused ultrasound.
EDAP: 3.23 (-0.02)
EDAP HIFU and Lithotripsy Devices Showcased at 31st Annual European Association of Urology Congress
GlobeNewswire - Thu Mar 17, 7:30AM CDT
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that its HIFU and lithotripsy devices were highlighted at the European Association of Urology (EAU) 2016 Annual Congress held in Munich, Germany, on March 11-15, 2016.
EDAP: 3.23 (-0.02)
EDAP Announces Sylvester Comprehensive Cancer Center in Miami as First Certified U.S. Ablatherm(R) Robotic HIFU Site
GlobeNewswire - Thu Mar 10, 7:30AM CST
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that Sylvester Comprehensive Cancer Center at the University of Miami is the first site in the U.S. to be fully certified in the use of Ablatherm Robotic HIFU.
EDAP: 3.23 (-0.02)
First Patients Treated With EDAP's Ablatherm(R) Robotic HIFU in New York
GlobeNewswire - Mon Mar 07, 7:40AM CST
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced the first prostate ablation treatments performed at Gramercy Surgery Center in New York, NY, using the Company's FDA-cleared Ablatherm Robotic HIFU. Dr. Ivan Grunberger, Chief of Urology at New York Methodist Hospital and Professor of Clinical Urology at Weill Cornell Medical College, performed the procedures. He was assisted by Dr. Judd Boczko, an Assistant Clinical Professor of Urology at New York Medical College who practices with Westmed Medical Group.
EDAP: 3.23 (-0.02)
First Prostate Ablation Treatments Performed Using EDAP's FDA Approved Ablatherm(R) Robotic HIFU at Sylvester Comprehensive Cancer Center, in Miami, Florida
GlobeNewswire - Mon Jan 25, 7:30AM CST
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced the first prostate ablation treatments performed at Sylvester Comprehensive Cancer Center, Miami, using FDA approved Ablatherm Robotic HIFU. Sylvester Center will serve as the Ablatherm HIFU training and proctoring center for the U.S. East Coast and a door opened to the South American Market.
EDAP: 3.23 (-0.02)
EDAP Announces Results of World's First Focal HIFU Trial
GlobeNewswire - Tue Jan 19, 7:30AM CST
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced the publication of long term results of Ablatherm Focal HIFU in the peer reviewed journal "Prostate Cancer and Prostatic Diseases," part of the Nature Publishing Group.
EDAP: 3.23 (-0.02)
EDAP Reports Sale of Ablatherm Robotic HIFU to Sylvester Comprehensive Cancer Center
GlobeNewswire - Mon Dec 21, 7:30AM CST
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced the sale of an Ablatherm Robotic HIFU device to Sylvester Comprehensive Cancer Center, part of UHealth - the University of Miami Health System.
EDAP: 3.23 (-0.02)
EDAP Receives Russian Regulatory Approval for Focal One(R) HIFU Device
GlobeNewswire - Fri Dec 11, 7:30AM CST
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that Russia's Federal Service for Surveillance in Healthcare (Roszdravnadzor) has approved Focal One for sale in Russia. Russia is currently the largest market for EDAP's Ablatherm(R) robotic HIFU technology.
EDAP: 3.23 (-0.02)
EDAP Reports Installation of Ablatherm Robotic HIFU at University of Southern California
GlobeNewswire - Wed Dec 09, 7:30AM CST
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced the first installation of Ablatherm Robotic HIFU at University of Southern California, Keck Medicine of USC, which will become the first reference and training center for Ablatherm Robotic HIFU in the U.S.
EDAP: 3.23 (-0.02)
EDAP First Quarter 2016 Revenue Increases 40% Year-over-Year to EUR8.7 Million
GlobeNewswire - Wed May 18, 6:00AM CDT
-- First quarter 2016 HIFU Division revenue increased 102% year-over-year
EDAP: 3.23 (-0.02)
EDAP to Report First Quarter 2016 Results on May 18, 2016
GlobeNewswire - Tue May 10, 7:30AM CDT
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that it plans to release financial results for the first quarter ended March 31, 2016, on May 18, 2016, during pre-market hours.
EDAP: 3.23 (-0.02)
EDAP Announces Presentations and Live Demonstrations of Ablatherm(R) Robotic HIFU at 2016 American Urology Association Annual Meeting, May 6-10, 2016
GlobeNewswire - Wed May 04, 7:30AM CDT
Company to Participate in Two Plenary Sessions and Five Poster Sessions
EDAP: 3.23 (-0.02)
EDAP Receives Brazilian Regulatory Approval for Focal One(R) HIFU Device
GlobeNewswire - Thu Apr 28, 7:30AM CDT
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that The Brazilian Health Surveillance Agency (Anvisa) has approved Focal One for sale in Brazil.
EDAP: 3.23 (-0.02)
Houston Methodist Hospital, Houston, TX Acquires and Installs EDAP's Ablatherm(R) Robotic HIFU
GlobeNewswire - Mon Apr 25, 7:36AM CDT
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced the sale and installation of Ablatherm Robotic HIFU at Houston Methodist Hospital, Houston, Texas. The hospital is the first location in Texas to install EDAP's noninvasive HIFU device for the ablation of prostate tissue.
EDAP: 3.23 (-0.02)
EDAP's Ablatherm(R) Robotic HIFU Deployed by HIFU Solution
GlobeNewswire - Mon Apr 18, 7:30AM CDT
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced the first prostate ablation treatments performed in Orlando, Florida, using the Company's FDA-cleared Ablatherm Robotic HIFU.
EDAP: 3.23 (-0.02)
EDAP TMS SA Closes $11.5 Million Registered Direct Offering
GlobeNewswire - Thu Apr 14, 2:15PM CDT
Positions EDAP to Accelerate U.S. Sales and Marketing Expansion for HIFU
EDAP: 3.23 (-0.02)
EDAP TMS SA to Raise $11.5 Million in Registered Direct Offering
GlobeNewswire - Thu Apr 07, 8:13AM CDT
EDAP TMS SA (Nasdaq:EDAP), a global leader in therapeutic ultrasound, announced that it has entered into definitive agreements with certain institutional investors for a registered direct placement of 3,283,284 ordinary shares in the form of American Depositary Shares ("ADSs"
at a price of $3.50 per share. EDAP: 3.23 (-0.02)
EDAP Submits 510(k) Application for FDA Clearance of Focal One HIFU
GlobeNewswire - Wed Apr 06, 6:55AM CDT
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that it has submitted a 510(k) application to the U.S. Food and Drug Administration (FDA) for the clearance of its next generation HIFU device: the Focal One. This submission follows the November 2015 FDA clearance of Ablatherm Robotic HIFU for the ablation of prostate tissue.
EDAP: 3.23 (-0.02)
EDAP Reports 20% Revenue Growth to EUR 32.3 Million and EUR 0.5 Million Operating Profit for Full-year 2015
GlobeNewswire - Mon Apr 04, 6:00AM CDT
-- Obtained FDA clearance in November 2015 for Ablatherm Robotic HIFU;
EDAP: 3.23 (-0.02)
EDAP to Report Fourth Quarter and Full Year 2015 Results on April 4, 2016
GlobeNewswire - Thu Mar 24, 7:30AM CDT
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that it plans to release financial results for the fourth quarter and full year ended December 31, 2015, on April 4, 2016, during pre-market hours.
EDAP: 3.23 (-0.02)
EDAP HIFU Advancements Highlighted at International Symposium on Therapeutic Ultrasound
GlobeNewswire - Tue Mar 22, 7:30AM CDT
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that its advancements in High Intensity Focused Ultrasound (HIFU) were highlighted at the International Symposium on Therapeutic Ultrasound (ISTU 2016), which took place from March 14-17, 2016, in Tel Aviv, Israel. At ISTU 2016, HIFU experts from EDAP and the Company's long-time academic partner, INSERM, presented their most recent advances in the development of therapeutic focused ultrasound.
EDAP: 3.23 (-0.02)
EDAP HIFU and Lithotripsy Devices Showcased at 31st Annual European Association of Urology Congress
GlobeNewswire - Thu Mar 17, 7:30AM CDT
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that its HIFU and lithotripsy devices were highlighted at the European Association of Urology (EAU) 2016 Annual Congress held in Munich, Germany, on March 11-15, 2016.
EDAP: 3.23 (-0.02)
EDAP Announces Sylvester Comprehensive Cancer Center in Miami as First Certified U.S. Ablatherm(R) Robotic HIFU Site
GlobeNewswire - Thu Mar 10, 7:30AM CST
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that Sylvester Comprehensive Cancer Center at the University of Miami is the first site in the U.S. to be fully certified in the use of Ablatherm Robotic HIFU.
EDAP: 3.23 (-0.02)
First Patients Treated With EDAP's Ablatherm(R) Robotic HIFU in New York
GlobeNewswire - Mon Mar 07, 7:40AM CST
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced the first prostate ablation treatments performed at Gramercy Surgery Center in New York, NY, using the Company's FDA-cleared Ablatherm Robotic HIFU. Dr. Ivan Grunberger, Chief of Urology at New York Methodist Hospital and Professor of Clinical Urology at Weill Cornell Medical College, performed the procedures. He was assisted by Dr. Judd Boczko, an Assistant Clinical Professor of Urology at New York Medical College who practices with Westmed Medical Group.
EDAP: 3.23 (-0.02)
First Prostate Ablation Treatments Performed Using EDAP's FDA Approved Ablatherm(R) Robotic HIFU at Sylvester Comprehensive Cancer Center, in Miami, Florida
GlobeNewswire - Mon Jan 25, 7:30AM CST
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced the first prostate ablation treatments performed at Sylvester Comprehensive Cancer Center, Miami, using FDA approved Ablatherm Robotic HIFU. Sylvester Center will serve as the Ablatherm HIFU training and proctoring center for the U.S. East Coast and a door opened to the South American Market.
EDAP: 3.23 (-0.02)
EDAP Announces Results of World's First Focal HIFU Trial
GlobeNewswire - Tue Jan 19, 7:30AM CST
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced the publication of long term results of Ablatherm Focal HIFU in the peer reviewed journal "Prostate Cancer and Prostatic Diseases," part of the Nature Publishing Group.
EDAP: 3.23 (-0.02)
EDAP Reports Sale of Ablatherm Robotic HIFU to Sylvester Comprehensive Cancer Center
GlobeNewswire - Mon Dec 21, 7:30AM CST
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced the sale of an Ablatherm Robotic HIFU device to Sylvester Comprehensive Cancer Center, part of UHealth - the University of Miami Health System.
EDAP: 3.23 (-0.02)
EDAP Receives Russian Regulatory Approval for Focal One(R) HIFU Device
GlobeNewswire - Fri Dec 11, 7:30AM CST
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that Russia's Federal Service for Surveillance in Healthcare (Roszdravnadzor) has approved Focal One for sale in Russia. Russia is currently the largest market for EDAP's Ablatherm(R) robotic HIFU technology.
EDAP: 3.23 (-0.02)
EDAP Reports Installation of Ablatherm Robotic HIFU at University of Southern California
GlobeNewswire - Wed Dec 09, 7:30AM CST
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced the first installation of Ablatherm Robotic HIFU at University of Southern California, Keck Medicine of USC, which will become the first reference and training center for Ablatherm Robotic HIFU in the U.S.
EDAP: 3.23 (-0.02)
